Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcription profiling of human Wilms tumor versus stratagene universal reference

ABSTRACT: Gene expression comparison of Wilms tumor RNA versus Stratagene Universal reference RNA

ORGANISM(S): Homo sapiens

SUBMITTER: Fred van Ruissen

PROVIDER: E-GEOD-1158 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Evaluation of the similarity of gene expression data estimated with SAGE and Affymetrix GeneChips.

van Ruissen Fred F Ruijter Jan M JM Schaaf Gerben J GJ Asgharnegad Lida L Zwijnenburg Danny A DA Kool Marcel M Baas Frank F

BMC genomics 20050614

<h4>Background</h4>Serial Analysis of Gene Expression (SAGE) and microarrays have found a widespread application, but much ambiguity exists regarding the evaluation of these technologies. Cross-platform utilization of gene expression data from the SAGE and microarray technology could reduce the need for duplicate experiments and facilitate a more extensive exchange of data within the research community. This requires a measure for the correspondence of the different gene expression platforms. To ...[more]

PMID: 15955238

Similar Datasets

Wilms tumor versus Stratagene Universal Reference

Project description:Gene expression comparison of Wilms tumor RNA versus Stratagene Universal reference RNA Keywords: repeat sample

2004-12-31 | GSE1158 | GEO

Homo sapiens

Project description:Wilms tumor versus Stratagene Universal Reference

| PRJNA87293 | ENA

Stratagene Universal Human RNA Hybridized to Affymetrix U133 Plus 2.0 and U133 A Chips

Project description:Stratagene universal human RNA hybridized to both U133 Plus 2.0 and U133 A arrays. Keywords: Affymetrix platform comparison

2006-07-25 | GSE3061 | GEO

Transcription profiling of human Stratagene Universal RNA on Affymetrix U133 Plus 2.0 and U133 A Chips

Project description:Stratagene universal human RNA hybridized to both U133 Plus 2.0 and U133 A arrays. Experiment Overall Design: Stratagene universal human RNA was processed using 5 aliquots of 2 ug each. The samples were hybridized to both 133 Plus 2.0 and 133 A arrays.

2008-06-12 | E-GEOD-3061 | biostudies-arrayexpress

Transcription profiling of Stratagene human universal reference RNA labelled with different labelling protocols to test labelling protocols

Project description:Considerable variation in gene expression data from different DNA microarray platforms has been demonstrated. However, no characterization of the source of variation arising from labeling protocols has been performed. To analyze the variation associated with T7-based RNA amplification/labeling methods, aliquots of the Stratagene Human Universal Reference RNA were labeled using 3 eukaryotic target preparation methods and hybridized to a single array type (Affymetrix U95Av2). Variability was measured in yield and size distribution of labeled products, as well as in the gene expression results. All methods showed a shift in cRNA size distribution, when compared to un-amplified mRNA, with a significant increase in short transcripts for methods with long IVT reactions. Intra-method reproducibility showed correlation coefficients >0.99, while inter-method comparisons showed coefficients ranging from 0.94 to 0.98 and a nearly two-fold increase in coefficient of variation. Fold amplification for each method was positively correlated with the number of present genes. Two factors that introduced significant bias in gene expression data were observed: a) number of labeled nucleotides that introduces sequence dependent bias, and b) the length of the IVT reaction that introduces a transcript size dependent bias. This study provides evidence of amplification method dependent biases in gene expression data.

2007-07-24 | E-GEOD-3254 | biostudies-arrayexpress

Transcriptomic Characterization of wilms tumor

Project description:Wilms tumor (WT) is the most common renal malignancy in children. So we aim to investigate the transcriptomic map of Wilms tumor.

2022-05-18 | GSE138869 | GEO

miRNA and Wilms' tumor

Project description:This SuperSeries is composed of the following subset Series: GSE17342: The role of miRNA in Wilms' tumorigenesis GSE28397: Copy number alteration in Wilms' tumor with custom-designed miRNA probes GSE28400: MIR-204 target gene Refer to individual Series

2012-03-30 | E-GEOD-28401 | biostudies-arrayexpress

miRNA and Wilms' tumor

Project description:miRNA and Wilms' tumor

| PRJNA139175 | ENA

Circulating miRNA in serum of Wilms tumor patients

Project description:Abstract: Background: MiRNA signatures in human sera have been reported for various tumor diseases. Here we generated miRNA profiles analyzing 1205 mature miRNA transcripts of serum samples of Wilms tumor patients, taken prior and after chemotherapy according to SIOP protocol 2001. Using a feature subset selection filter approach we identified a minimal number of miRNAs with a maximum contribution for the classification between treated and untreated patients and between patients and controls. Results: Analyzing 1205 mature miRNAs, we separated controls and Wilms tumor patients prior chemotherapy with an accuracy of 0.81. We obtained a similar accuracy (0.82) for the separation between controls and sera of Wilms tumor patients after preoperative chemotherapy. We identified 23 miRNAs that were differentially expressed in both comparisons. Subset selection improved the overall classification accuracy between controls and Wilms tumor patients prior and after chemotherapy to 0.94 and 0.91, respectively. Subset selection also allowed separating between Wilms tumor patients prior and after chemotherapy with an accuracy of 0.98. Conclusion: Our analysis identified serum based miRNA signatures that allowed separating between controls, untreated Wilms tumor patients, and Wilms tumor patients after chemotherapy with high accuracy for each of these comparisons.

2014-12-31 | GSE48137 | GEO

Proteasome inhibition sensitizes anaplastic Wilms tumor to actinomycin D

Project description:Wilms tumor is the most common kidney cancer in children, and anaplastic Wilms tumor is the most chemoresistant histological subtype. Here we explore how anaplastic Wilms tumor cells evade the common chemotherapeutic drug actinomycin D, which inhibits ribosomal biogenesis. We found that, when ribosomal capacity is limited by actinomycin D treatment, anaplastic Wilms tumor cells preferentially translate proteasome components and upregulate proteasome activity. Accordingly, increased proteasome levels are associated with anaplastic histology and with worse prognosis in Wilms tumor. Lastly, we show that the proteasome inhibitor bortezomib sensitizes cells to actinomycin D treatment both in vitro and in vivo.

2024-06-20 | GSE270330 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data